GlassScriptPhysician profile
Andrew Robert Sacks
NPI 1447561949
$6,278.62
in general payments reported to CMS, 2019-2025
25 companies · $672 in 2025
The $672 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $2,696 · 2021: $818 · 2022: $360 · 2023: $564 · 2024: $756 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,852 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,851.78 |
| Education | $139.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $2,726.51 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $452.82 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $452.05 | 2019-2025 | Rayaldee |
| Amgen INC. | $443.41 | 2022-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $327.27 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $279.04 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $218.99 | 2020-2023 | Acthar |
| Vifor Pharma, INC. | $195.79 | 2019-2025 | Veltassa, Korsuva |
| Bard Peripheral Vascular, INC. | $179.48 | 2020-2023 | Fluency Endovascular Stent Graft |
| Horizon Therapeutics Plc | $172.78 | 2021-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $151.68 | 2021-2025 | |
| Boston Scientific Corporation | $126.31 | 2019 | |
| Akebia Therapeutics INC | $96.46 | 2019-2021 | |
| Calliditas Therapeutics US INC. | $94.57 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $72.52 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $49.64 | 2020-2023 | Ultomiris |
| Ultragenyx Pharmaceutical INC. | $45.07 | 2020-2023 | |
| Outset Medical INC | $41.89 | 2024 | |
| Daiichi Sankyo INC. | $40.48 | 2020-2025 | Injectafer |
| Recordati_rare_diseases_inc. | $24.54 | 2023 | Signifor Lar, Isturisa |
| Alnylam Pharmaceuticals INC. | $24.20 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.14 | 2022 | |
| Renalytix Ai, INC. | $16.98 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Aurinia Pharma U.S., INC. | $15.95 | 2024 | Lupkynis |
| Advanced Oxygen Therapy INC. | $10.05 | 2025 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Sacks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.